The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A systematic review and network meta-analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer.
 
Mohamad Bassam Sonbol
No Relationships to Disclose
 
Raed Benkhadra
No Relationships to Disclose
 
Zhen Wang
No Relationships to Disclose
 
Belal Firwana
No Relationships to Disclose
 
Kabir Mody
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Genentech/Roche; Merrimack; Vicus Therapeutics
Research Funding - Agios; ARIAD; ArQule; FibroGen; MedImmune; Senhwa Biosciences; Taiho Pharmaceutical; TRACON Pharma
 
Pashtoon Murtaza Kasi
Consulting or Advisory Role - Ipsen (Inst); Taiho Pharmaceutical (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst)
 
Joleen Marie Hubbard
Consulting or Advisory Role - Genentech/Roche (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); Merck (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst)
 
M. Hassan Murad
No Relationships to Disclose
 
Daniel H. Ahn
Consulting or Advisory Role - Astellas Pharma; Cardinal Health; Celltrion (I); Eisai; Lexicon; Merrimack; Paradigm
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Celgene; Celgene (Inst); Genentech/Roche; Glenmark; Incyte (Inst); Ipsen (Inst); Lilly; Lilly (Inst); Merck (Inst); NCCN; Regeneron; Research to Practice; Roche/Genentech (Inst)
Research Funding - NCCN; NCI; Oncolytics
Other Relationship - ARMO BioSciences; Exelixis; Exelixis; Merck; Polaris; Sillajen